Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
Open accessAbstract
OBJECTIVE: The purpose of this study was to identify predictors of incident diabetes during follow-up of nondiabetic patients with chronic heart failure (CHF) in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. RESEARCH DESIGN AND METHODS: A total of 1,620 nondiabetic patients had full baseline datasets. We compared baseline demographic, medication, and laboratory data for patients who did or did not develop diabetes and conducted logistic regression and receiver operator characteristic curve analyses. RESULTS: Over a median period of 2.8 years, 126 of the 1,620 patients (7.8%) developed diabetes. In multiple logistic regression analysis, the following baseline characteristics were independently associated with incident diabetes in decreasing order of significance by stepwise selection: higher A1C (odds ratio [OR] 1.78 per 1 SD increase; P < 0.0001), higher BMI (OR 1.64 per 1 SD increase; P < 0.0001), lipid-lowering therapy (OR 2.05; P = 0.0005), lower serum creatinine concentration (OR 0.68 per 1 SD increase; P = 0.0018), diuretic therapy (OR 4.81; P = 0.003), digoxin therapy (OR 1.65; P = 0.022), higher serum alanine aminotransferase concentration (OR 1.15 per 1 SD increase; P = 0.027), and lower age (OR 0.81 per 1 SD increase; P = 0.048). Using receiver operating characteristic curve analysis, A1C and BMI yielded areas under the curve of 0.723 and 0.712, respectively, increasing to 0.788 when combined. Addition of other variables independently associated with diabetes risk minimally improved prediction of diabetes. CONCLUSIONS: In nondiabetic patients with CHF in CHARM, A1C and BMI were the strongest predictors of the development of diabetes. Other minor predictors in part reflected CHF severity or drug-associated diabetes risk. Identifying patients with CHF at risk of diabetes through simple criteria appears possible and could enable targeted preventative measures.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with HF, data from observational and clinical trials demonstrate an increased risk for new-onset T2DM compared to patients without HF.
“In patients with HF, data from observational and clinical trials demonstrate an increased risk for new-onset T2DM compared to patients without HF.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [56]
In the CHARM program, 7.8% of patients developed T2DM over 2.8 years.
“as demonstrated by the CHARM program, in which 7.8% of patients developed T2DM over 2.8 years.55,56”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 26 · Cited by 76
- Authors
- Preiss, D., Zetterstrand, S., McMurray, J. J. V., Östergren, J., Michelson, E. L., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., Gerstein, H. C., Sattar, N., & for the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators
- Affiliations
- University of Glasgow (GB)
- AstraZeneca (Sweden) (SE)
- Karolinska University Hospital (SE)
- AstraZeneca (United States) (US)
- Duke Medical Center (US)
- HGM-McMaster Clinic, Hamilton, Ontario, Canada;
- University of Gothenburg (SE)
- Brigham and Women's Hospital (US)
- Population Health Research Institute (CA)
- Corresponding author
- Sattar, Naveed
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-02-05
- Volume
- 32
- Issue
- 5
- Pages
- 915-920
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2671104
- OpenAlex
- W2147980767
- Cited by
- 76
- References
- 26
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 6 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 2 · 2012: 7
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- chronic heart failure, new-onset diabetes, diabetes risk prediction, HbA1c, body mass index, candesartan, diuretic therapy, digoxin, serum creatinine, alanine aminotransferase, lipid-lowering therapy, drug-induced diabetes, CHARM trial
- MeSH terms
- Aged, Blood Pressure, Chronic Disease, Diabetes Mellitus, Female, Follow-Up Studies, Heart Failure, Glycated Hemoglobin, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Smoking, Models, Statistical, Body Mass Index, Odds Ratio, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review